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Loss of BMPR2 leads to high bone mass due to increased
osteoblast activity
Jonathan W. Lowery1,2, Giuseppe Intini3, Laura Gamer2, Sutada Lotinun3,4, Valerie S. Salazar2, Satoshi Ote2,
Karen Cox2, Roland Baron3 and Vicki Rosen2,*
ABSTRACT
Imbalances in the ratio of bone morphogenetic protein (BMP)
versus activin and TGFb signaling are increasingly associated with
human diseases yet the mechanisms mediating this relationship
remain unclear. The type 2 receptors ACVR2A and ACVR2B bind
BMPs and activins but the type 2 receptor BMPR2 only binds
BMPs, suggesting that type 2 receptor utilization might play a
role in mediating the interaction of these pathways. We tested
this hypothesis in the mouse skeleton, where bone mass is
reciprocally regulated by BMP signaling and activin and TGFb
signaling. We found that deleting Bmpr2 in mouse skeletal
progenitor cells (Bmpr2-cKO mice) selectively impaired activin
signaling but had no effect on BMP signaling, resulting in an
increased bone formation rate and high bone mass. Additionally,
activin sequestration had no effect on bone mass in Bmpr2-cKO
mice but increased bone mass in wild-type mice. Our findings
suggest a novel model whereby BMPR2 availability alleviates
receptor-level competition between BMPs and activins and where
utilization of ACVR2A and ACVR2B by BMPs comes at the expense
of activins. As BMP and activin pathway modulation are of current
therapeutic interest, our findings provide important mechanistic
insight into the relationship between these pathways in human
health.
KEY WORDS: BMP, Activin, BMPR2, Bone mass, Osteoblast,
Osteoporosis
INTRODUCTION
All TGFb superfamily cytokines [BMPs, GDFs, activin and
activin-like ligands, such as GDF8 (also known as myostatin)
and GDF11 (hereafter collectively referred to as ‘activins’ for
simplicity), and TGFb] can be categorized based on their
activation of one of two distinct downstream pathways – either
through SMAD1, SMAD5 and SMAD8 (hereafter denoted as
SMAD1/5/8; note that SMAD8 is also known as SMAD9) or
SMAD2 and SMAD3 (hereafter denoted as SMAD2/3), which are
the canonical BMP signaling and activin and TGFb signaling
effectors, respectively (Lowery and de Caestecker, 2010). The
canonical BMP pathway and activin and TGFb pathway
antagonize one another in numerous physiological contexts,
including in early embryonic development, where SMAD2
antagonizes SMAD1 to establish body patterning (Yamamoto
et al., 2009), in angiogenesis, where the balance of SMAD1/5/8
and SMAD2/3 establishes an angiogenic switch between
activation and resolution phases (Goumans et al., 2003), in cell
fate of type 2 alveolar epithelial cells, where trans-differentiation
to a type 1 alveolar program is promoted by SMAD2/3, but
restricted by SMAD1/5/8 (Zhao et al., 2013), during maintenance
of epithelial cell polarity, where SMAD1/5/8 restricts the TGFb-
induced epithelial–mesenchymal transition (Saitoh et al., 2013),
and during regulation of skeletal muscle mass, where SMAD1/5/8
and SMAD2/3 signaling inversely impact on muscle hypertrophy
(Sartori et al., 2013; Winbanks et al., 2013). Moreover, imbalances
in the ratio of TGFb superfamily cytokines are increasingly
associated with human diseases, including pulmonary and kidney
fibrosis (Izumi et al., 2006; Nguyen and Goldschmeding, 2008),
glaucoma (Wordinger et al., 2007; Zode et al., 2009), asthma
(Stumm et al., 2014) and pulmonary arterial hypertension (Han et al.,
2013; Morrell et al., 2001). However, the mechanisms that allow the
BMP pathway and the activin and TGFb pathway to antagonize one
another remain unclear. For instance, competition for the shared
transcription factor SMAD4 (Candia et al., 1997; Sartori et al., 2013)
and regulation of downstream target genes (Oshimori and Fuchs,
2012) are likely insufficient general explanations because SMAD4,
which is common to both pathways, is not always limiting (Piek
et al., 1999) and target genes vary greatly by biological context
(Massagué, 2012). Less attention has been paid, however, to
potential regulation at the level of pathway activation via receptor
utilization, which could influence the ratio of signaling upstream of
any additional mechanisms.
TGFb superfamily ligands signal through heteromeric
combinations of type 1 and type 2 receptors, and both receptor
types are essential to elicit downstream signaling. BMPs, activins
and TGFbs generally utilize separate type 1 receptors (Hinck,
2012). In contrast, TGFb has a unique type 2 receptor, whereas
the type 2 receptors ACVR2A and ACVR2B (hereafter denoted
ACVR2A/B) bind activins with high affinity but also bind BMPs
with comparatively lower affinity. BMPs therefore can utilize
ACVR2A/B and also the BMP-specific type 2 receptor, BMPR2,
allowing for potential competition for ACVR2A/B by BMPs and
activin based on the availability of BMPR2. We examined this
hypothesis in the context of the mouse skeleton, taking advantage
of the fact that postnatal bone formation and mineralization is
under tight reciprocal regulation by BMPs and activins (Alves
et al., 2013; Eijken et al., 2007; Fajardo et al., 2010; Ikenoue
et al., 1999; Koncarevic et al., 2010; Li et al., 2013; Lotinun et al.,
2010; Matsumoto et al., 2012; Mishina et al., 2004; Nicks et al.,
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2009; Pearsall et al., 2008; Perrien et al., 2007; Ruckle et al.,
2009; Sakai et al., 2000; Sherman et al., 2013; Simic et al., 2006;
Zhang et al., 2009; Zhao et al., 2002). Surprisingly, engineering
specific deletion of BMPR2 in bone-forming cells (Bmpr2-cKO
mice) selectively reduces activin pathway activation but has no
apparent effect on BMP signaling. Additionally, Bmpr2-cKO
mice develop substantially higher bone mass and bone mineral
density by 9 weeks of age due to a higher bone formation rate,
which is consistent with impaired activin signaling (Alves et al.,
2013; Eijken et al., 2007; Ikenoue et al., 1999; Perrien et al.,
2007). Our findings suggest a novel model whereby availability
of BMPR2 in target cells permits partial segregation of ACVR2A/
B to the activin pathway and increased BMP utilization of
ACVR2A/B comes at the expense of activin signaling.
RESULTS
Type 2 BMP and activin receptor expression in bone cells
Each of the type 2 receptors Bmpr2, Acvr2a and Acvr2b are expressed
in the postnatal skeleton (Fig. 1A; Liu et al., 2012). To remove
BMPR2 from bone-forming cells, we crossed Bmpr2floxed/floxed mice
to Paired-related homeobox gene 1 (Prx1)-Cre transgenic mice
(Logan et al., 2002), which accomplishes widespread recombination
and subsequent permanent loss of BMPR2 in osteoprogenitors,
osteoblasts and osteocytes of the limb skeleton (Almeida et al.,
2013; Logan et al., 2002). Loss of full-length BMPR2 in Bmpr2-
cKO; Prx1-Cre mice (Bmpr2-cKO mice) was confirmed at the
mRNA and protein levels (Gamer et al., 2011). Importantly, the
bone-specific expression levels of Acvr2a and Acvr2b are
unchanged in the bones of Bmpr2-cKO mice (Fig. 1B,C; Gamer
et al., 2011).
Removal of BMPR2 selectively reduces activated SMAD2/3 in
bone cells
We next performed western blots on marrow-free femora lysates
to investigate whether signaling changes are associated with loss
of BMPR2 expression and found that the level of phosphorylated
(i.e. activated) SMAD1/5/8 was unchanged in Bmpr2-cKO mice
at 4 weeks and 9 weeks of age (supplementary material Fig. S1A;
Fig. 1D). Given that type 2 receptor occupancy is required for
BMP signaling, ACVR2A/B appear to functionally compensate
for loss of BMPR2 in bone cells in vivo. To examine whether this
shift in receptor usage by BMPs has an effect on activin signaling,
we next evaluated the level of phosphorylated (i.e. activated)
SMAD2/3. Whereas activated SMAD2/3 was unaffected in
Bmpr2-cKO mice at 4 weeks of age (supplementary material
Fig. S1A), the level of activated SMAD2/3 was substantially
reduced in Bmpr2-cKO mice at 9 weeks of age (Fig. 1E).
To examine, in a cell-specific manner, whether reduced
SMAD2/3 activation is directly related to loss of BMPR2, we
isolated primary osteoblasts from Bmpr2-floxed mice, which
express each of the type 2 receptors Bmpr2, Acvr2a and Acvr2b
(Fig. 2A), and induced recombination using adenoviral delivery
of Cre. Loss of full-length BMPR2 was confirmed at the mRNA
(Fig. 2B) and protein (Fig. 2C) levels. Consistent with our results
in femora lysates, the basal level of canonical activin and TGFb
signaling was reduced, whereas canonical BMP signaling was
unaffected in Bmpr2-cKO osteoblasts (Fig. 2C,D). This does not
appear to be due to decreased activin ligand availability given
that expression levels of the activin subunits Inhba and Inhbb and
the antagonists inhibin a (Inha) and follistatin were unchanged
in Bmpr2-cKO osteoblasts (supplementary material Fig. S2A).
Note that because Bmpr2-cKO osteoblasts were responsive to
exogenous activin A (supplementary material Fig. S2B), reduced
basal SMAD2/3 activation in this cell population is not due to a
requirement for BMPR2 in activin signaling.
High bone mass in Bmpr2-cKOmice due to an increased bone
formation rate
We next examined the impact of loss of BMPR2 on postnatal
bone physiology in vivo. Although limb skeletogenesis and
expression of bone markers are unchanged in Bmpr2-cKO mice at
birth (Gamer et al., 2011) and at 4 weeks of age (supplementary
material Fig. S3A), both male and female Bmpr2-cKO mice
display high trabecular bone mass and increased bone mineral
Fig. 1. Effects of removing Bmpr2 in bone. (A) RT-PCR for Bmpr2, Acvr2a, and Acvr2b expression in wild-type (WT) 15-week-old mouse humerus. NTC, no
DNA template control. (B,C) Expression of Acvr2a (B) and Acvr2b (C) in humerii of 4-week-old Bmpr2-cKO mice compared to Bmpr2-floxed littermates
(n§4 per genotype). (D,E) Western blots for phosphorylated isoforms of SMAD1/5/8 (pS1/5/8) and SMAD2/3 (pS2/3) relative to total SMAD1 or SMAD2.
Lysates are from marrow-free femora of female mice at 9 weeks of age. Densitometry are normalized to Bmpr2-floxed from n53 each genotype. aP,0.05
compared with Bmpr2-floxed. The vertical bar in D indicates removal of intervening lane so that samples most representative of group mean are shown; the blot
image with the intervening lane present is shown in supplementary material Fig. S1B.












density in the tibia by 9 weeks of age (Table 1; Fig. 3A). As an
internal control, we examined the L5 vertebrae of Bmpr2-cKO
mice (supplementary material Table S1), which is outside the
Prx1-Cre expression domain. Bone mass is unaffected at this site,
confirming that increased tibial bone mass is specifically due to
Cre-dependent loss of Bmpr2.
We then performed detailed histomorphometric analyses
(Dempster et al., 2013) to examine the cellular mechanism(s)
responsible for the high bone mass in Bmpr2-cKO mice. Whereas
osteoblast density and coverage of individual bone surfaces
were unchanged in Bmpr2-cKO mice (Table 2), in vivo calcein
labeling indicated that the percentage of bone surface undergoing
mineralization tended to be higher in Bmpr2-cKO mice during the
labeling period of 9 and 10 weeks of age. Bone mineral apposition
rate was also significantly increased at this time (Table 2),
resulting in a substantially elevated bone formation rate (Fig. 3B;
Table 2). Although Prx1-Cre is not expressed in osteoclasts
(Almeida et al., 2013; Kolanczyk et al., 2007), we examined
whether Bmpr2-cKO mice displayed secondary defects in bone
resorption. Osteoclast density, osteoclast coverage, and the
percentage bone surface undergoing resorption were unchanged
in Bmpr2-cKO mice (Table 2). Furthermore, the increase in bone
volume in Bmpr2-cKO mice was proportional to the elevation in
bone formation rate (Fig. 3C), indicating that bone resorption is
unaffected by loss of BMPR2 in bone-forming cells.
Collectively, these findings indicate that the high bone mass we
observe in in Bmpr2-cKO mice is due to increased individual
osteoblast activity coincident with bone-specific reduction in
activin signaling.
Activin sequestration has no effect on bone mass in Bmpr2-
cKO mice
Our results led us to hypothesize that impaired activin signaling is
responsible for the high bone mass seen in Bmpr2-cKO mice. We
tested this idea by treating Bmpr2-floxed and Bmpr2-cKO mice
with ACVR2B receptor decoy (ACVR2B-Fc), which sequesters
activins with high affinity (Koncarevic et al., 2012; Sako et al.,
2010), selectively reduces SMAD2/3 activation (supplementary
material Fig. S4A,B; Ohsawa et al., 2006; Suragani et al., 2014;
Zhou et al., 2010) and increases bone mass (Attie et al., 2013;
Koncarevic et al., 2010). We reasoned that, if the reduced activin
signaling underlies high bone mass in Bmpr2-cKO mice, then
sequestration of activins with receptor decoy would have little or
no additional effect on bone mass.
Table 1. Bone volume and mineral density of proximal tibiae from Bmpr2-floxed and Bmpr2-cKO mice
Genotype
Age of mice Gender Bmpr2-floxed Bmpr2-cKO Change (%) P value
4 weeks Male BV/TV 0.073160.0028 0.072360.0036 21.20 ns
vBMD 71.1167.531 72.9066.541 2.50 ns
Female BV/TV 0.067360.0034 0.076960.0039 14.26 ns
vBMD 68.2066.040 84.3166.613 23.62 ns
9 weeks Male BV/TV 0.108260.0092 0.140560.0054 29.85 0.0132
vBMD 88.97611.41 124.069.965 39.37 0.0432
Female BV/TV 0.093660.0073 0.173560.0108 85.36 ,0.0001
vBMD 75.2867.357 164.5610.87 118.51 ,0.0001
15 weeks Male BV/TV 0.134160.0107 0.183560.0088 36.84 0.0024
vBMD 128.4612.33 185.3610.29 44.31 0.0024
Female BV/TV 0.100460.0069 0.152260.0088 51.59 0.0009
vBMD 95.5268.975 155.9611.25 63.21 0.0018
Change expressed as the percentage difference from gender-matched Bmpr2-floxed mice. n§6 each group. BV/TV, bone volume/tissue volume; vBMD,
volumetric bone mineral density expressed in mg hydroxyapatite per cubic centimeter; ns, not statistically significant.
Fig. 2. Reduced activated SMAD2/3 in Bmpr2-cKO osteoblasts. (A) RT-
PCR for Bmpr2, Acvr2a and Acvr2b expression in Bmpr2-floxed (WT)
osteoblasts. NTC, no DNA template control. (B–E) Loss of full-length Bmpr2
after adenoviral CMV-Cre delivery was confirmed at the mRNA level (B) by RT-
PCRand protein level (C) by western blotting.Western blots for phosphorylated
isoforms of SMAD1/5/8 (C, pS1/5/8) and SMAD2/3 (D, pS2/3) relative to total
SMAD1 or SMAD2. Densitometry (graphs on the right) represents three
independent isolation and transduction experiments normalized to control.Hprt
and b-actin serve as loading controls in B, and C and D, respectively. aP,0.002
compared with control by paired Student’s t-test.












Consistent with previous reports where activin sequestration
increased body weight gain and muscle mass (e.g. Cadena et al.,
2010; Lee et al., 2012; Lee et al., 2005; Wang and McPherron,
2012), activin sequestration in Bmpr2-cKO mice increased the
rate of body weight gain and the mass of the pectoralis major
muscle (Fig. 4A,B), which are cellular targets outside the Prx1-
Cre expression domain (Durland et al., 2008; Logan et al., 2002).
In contrast, activin sequestration had a statistically indiscernible
effect on trabecular bone mass and mineral density (Fig. 4C,D) in
the tibiae of Bmpr2-cKO mice. This does not appear to be due to
reduced activin ligand availability because the expression levels
of activin ligands and their antagonists were unchanged in the
bones of Bmpr2-cKO mice (supplementary material Fig. S3B);
similarly, BMP ligand and antagonist expression levels were
unaltered in Bmpr2-cKO bones (supplementary material Fig.
S3B). The ability of the ACVR2B receptor decoy to substantially
augment bone mass and mineral density as administered was
simultaneously confirmed in a small cohort of Bmpr2-floxed
mice (supplementary material Fig. S4E,F). The final bone mass
and density attained after activin sequestration was the same in
Bmpr2-floxed and Bmpr2-cKO mice, supporting the idea that
impaired activin pathway activation underlies the bone phenotype
we observe in Bmpr2-cKO mice.
DISCUSSION
Both BMPs and activins elicit pathway activation through
interaction with heteromeric complexes containing type 1 and
type 2 receptors (Zi et al., 2012). As represented in Fig. 5,
structural differences mean that BMP ligands interact with BMP
type 1 receptors (ALK1, ALK2, ALK3 and ALK6, also known as
ACVRL1, ACVR1, BMPR1A and BMPR1B, respectively),
whereas activin and related ligands (e.g. GDF8, GDF11)
interact with activin type 1 receptors (ALK4 and ALK7, also
known as ACVR1B and ACVR1C, respectively) (Hinck, 2012).
This distinction stratifies the activation of SMAD1/5/8 versus
SMAD2/3 downstream of BMPs and activins, respectively
(Fig. 5A). Structural differences also govern interaction of
ligands with type 2 receptors; only BMPs bind to the BMP-
specific type 2 receptor BMPR2 and activate SMAD1/5/8
(Fig. 5A) (Hinck, 2012), whereas the type 2 receptors
ACVR2A/B bind both BMPs and activins, engaging either
SMAD1/5/8 or SMAD2/3, respectively (Fig. 5A) (Hinck, 2012).
We hypothesized that BMPR2 is the preferred type 2 receptor for
BMPs in bone, and that by removing BMPR2 from bone-forming
cells we would create competition for a shared pool of ACVR2A/
B molecules (Fig. 5B). Surprisingly, competition for ACVR2A/B
led to a selective reduction in activin pathway signaling in bone
with no apparent alteration in BMP signaling. The high bone
mass phenotype we observed in Bmpr2-cKO mice is consistent
with previous reports detailing the negative effect of activin on
bone formation and matrix mineralization (Alves et al., 2013;
Bialek et al., 2013; Eijken et al., 2007; Fajardo et al., 2010;
Ikenoue et al., 1999; Koncarevic et al., 2010; Lotinun et al., 2010;
Pearsall et al., 2008; Perrien et al., 2007; Ruckle et al., 2009;
Sherman et al., 2013).
Collectively, our findings suggest that the availability of
BMPR2 in bone-forming target cells provides a novel mechanism
for establishing the relative amount of BMP to activin signaling.
When BMPR2 is reduced or absent, increased BMP utilization of
ACVR2A/B occurs at the expense of activin signaling. Although
unexpected, this finding is supported by the fact that, in general,
the affinity of BMPs for ACVR2A/B is in the same range as the
affinity for BMPR2 (Allendorph et al., 2006; Berasi et al., 2011;
Daly and Hearn, 2006; Greenwald et al., 2003; Greenwald et al.,
2004; Heinecke et al., 2009; Hu et al., 2010; Isaacs et al., 2010;
Kirsch et al., 2000; Knaus and Sebald, 2001; Koncarevic et al.,
2010; Rosenzweig et al., 1995; Sako et al., 2010; Sengle et al.,
2008), and BMPs also possess a flexible mode of receptor
complex assembly, which might enhance their ability to compete
with activins that have only a single mode of complex assembly
(Hinck, 2012). Because bone cells have abundant type 1 BMP
receptors (ALK2, ALK3 and ALK6, BioGPS Database), pre-
formed receptor complexes might also be biased toward BMP
binding. We do not believe our finding is only applicable to bone
cells, as Piek et al. have reported that BMP7 can effectively
compete with activin A for utilization of ACVR2A/B in human
embryonic carcinoma cells (Piek et al., 1999), and direct
competition for ACVR2A/B between BMP7 and the activin-like
Fig. 3. High bone mass in Bmpr2-cKO mice due to increased bone
formation rate. (A) Representative histological (1, 3) and mCT (2, 4) images
of female 9-week-old Bmpr2-floxed (1, 2) and Bmpr2-cKO (3, 4) mice. The
yellow arrowhead indicates increased trabecular bone volume in Bmpr2-cKO
femur. (B,C) Histomorphometric analyses of 10-week-old Bmpr2-floxed and
Bmpr2-cKO mice. n§8 each group. BFR, bone formation rate; BV, bone
volume; TV, tissue volume. aP,0.005 compared with Bmpr2-floxed by
Mann–Whitney test.












ligand GDF8 has been reported by Rebbapragada et al. during
adipogenesis (Rebbapragada et al., 2003).
Our model would predict that changes in either receptor or
ligand availability (for instance, through altered expression or
sequestration by extracellular antagonists) have the potential to
modulate the balance of BMP versus activin signaling in a given
cell. With respect to bone physiology, it is unknown whether the
expression profile of type 2 BMP and activin receptors changes
with age, but the ligands available to interact with type 2 BMP
and activin receptors do change: BMP levels decline with age,
which correlates with a decrease in ability to form new bone
(Moerman et al., 2004; Syftestad and Urist, 1982), and there is a
dramatic increase in circulating activin levels in adults of both
genders, especially in the last decades of life (Baccarelli et al.,
Table 2. Histomorphometric analysis of Bmpr2-floxed and Bmpr2-cKO mice
Genotype
Parameter Bmpr2-floxed Bmpr2-cKO Change (%) P value
Osteoblast density (N.Ob/B.Pm, per mm) 10.7861.180 12.0662.478 11.87 0.6839
Osteoblast coverage (Ob.S/BS, %) 13.2661.481 15.4163.270 16.21 0.6040
Surface undergoing mineralization (MS/BS, %) 32.3963.103 38.7561.676 19.64 0.0658
Trabecular mineral apposition rate (MAR, mm/day) 2.87160.1994 3.57160.1978 24.38 0.0278
Trabecular bone formation rate (BFR/BS, mm3/mm2/day) 327.1623.33 498.4625.89 52.37 0.0002
Endocortical mineral apposition rate (MAR, mm/day) 0.9760.36 2.2560.19 131.96 0.0070
Osteoclast density (N.Oc/B.Pm, per mm) 1.32760.2539 1.37260.2945 3.39 0.9126
Osteoclast coverage (Oc.S/BS, %) 3.42560.5214 3.32160.6657 23.04 0.9091
Surface undergoing erosion (ES/BS, %) 1.80360.3247 1.45360.3062 219.41 0.4521
Change expressed as the percentage difference from Bmpr2-floxed mice. n§8 for each group and parameter. B.Pm, bone perimeter; BFR, bone formation rate;
BS, bone surface; ES, eroded surface; MAR, mineral apposition rate; MS, mineralizing surface; N.Ob, number of osteoblasts; N.Oc, number of osteoclasts;
Ob.S, osteoblast surface; Oc.S, osteoclast surface.
Fig. 4. Effects of activin receptor decoy
administration in Bmpr2-cKO mice. (A) Rate of
body weight gain over a 5-week ACVR2B-Fc
treatment period in Bmpr2-cKO mice expressed as the
mean percentage change from subject body weight on
study day 0. (B–D) Effect of activin sequestration on
dry weight of pectoralis major (B) and tibia trabecular
bone volume (C) and bone mineral density (D) in
Bmpr2-cKO mice. Data for untreated cohorts in C,D
are also reported in Table 1. n§3 for all groups.
aP,0.05 compared with untreated Bmpr2-cKO.
Fig. 5. Model of BMP and activin signaling.
(A,B) Schematic of BMP and activin signaling in wild-
type (A) and Bmpr2-cKO (B) cells. The type 2
receptors ACVR2A/B are shared between the BMP
and activin pathways and elicit activation of either
SMAD1/5/8 (in complex with the type 1 receptors
ALK1, ALK2, ALK3 or ALK6) or SMAD2/3 (in complex
with the type 1 receptors ALK4 or ALK7) in response
to BMP or activin ligands, respectively (A). Removal
of the type 2 receptor BMPR2 requires all BMP and
activin signaling to utilize a common pool of ACVR2A/
B molecules (B).












2001; Hurwitz and Santoro, 2004). In other contexts, serum
immune-reactive activin is elevated further in patients with
several diseases including hyperthyroidism, liver cirrhosis,
chronic renal failure, advanced solid cancers, septicemia, acute
inflammation and type 2 diabetes (de Kretser et al., 2011; Harada
et al., 1996; Ueland et al., 2012). Our findings in bone raise the
possibility that type 2 receptor segregation and/or competition
could be a generalized mechanism by which BMP and activin
signaling interact. Given that modulation of both BMP and
activin pathways is of current clinical interest, a more detailed
understanding of the molecular relationship between these
pathways might provide insight into the development of new
therapeutic strategies that are widely applicable.
MATERIALS AND METHODS
Mouse lines
The generation of the mouse lines used in this study, Bmpr2floxed (Beppu
et al., 2005), Prx1-Cre transgenic (Logan et al., 2002), and Rosa26mT(mG)
Cre reporter mice (Muzumdar et al., 2007), have been described
previously. For experimental study groups, female Bmpr2floxed/floxed
mice were bred to male Bmpr2floxed/floxed; Prx1-Cre mice to generate
Bmpr2 conditional knockout (Bmpr2-cKO) mice and Cre-negative
Bmpr2floxed/floxed littermates (Bmpr2-floxed). Animals were killed by
exposure to CO2 followed by cervical dislocation. All animal
experiments were performed under supervision of the Harvard Medical
Area Standing Committee on Animals.
Osteoblast culture
Osteoblasts were isolated from the calvariae of newborn Bmpr2floxed/floxed;
Rosa26mT(mG) as described previously (Bakker and Klein-Nulend, 2003).
Isolated cells were pooled to reduce technical variability, expanded and
then split prior to delivery of adenovirus (Ad-CMV-Cre or Ad-CMV-
Empty; Baylor College of Medicine Vector Development Lab, Houston,
Texas, USA); recombination was monitored by expression of GFP from
the Rosa26mT(mG) reporter. Cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS; Gibco, Life Technologies, Grand Island, New York, NY); for
signaling studies, cells were serum-restricted in DMEM plus 2% FBS,
treated with 100 ng/ml activin A (R&D Systems) for 1 hour, lysed and
prepared for western blotting as described below.
Western blots
Western blotting was performed on protein isolates from primary
osteoblasts and marrow-free femora lysed in RIPA lysis buffer
supplemented with Halt Protease & Phosphatase Inhibitor Cocktail
(Thermo, Waltham, MA). Prior to lysis, femora were cleaned of soft
tissue, opened to expose the medullary cavity, centrifuged at 500 g for
2 minutes to separate marrow, and then homogenized using a Bullet
Blender (Next Advance, Averill Park, New York, NY). Blotting was
performed using antibodies against the following proteins: phosphorylated
(phospho)-SMAD1/5/8 (Cell Signaling, Danvers, MA), phospho-SMAD2/
3 (Cell Signaling), SMAD1 (Cell Signaling), SMAD2/3 (Cell Signaling),
b-actin (Sigma-Aldrich, St. Louis, MO), mouse IgG conjugated to
horseradish peroxidase (HRP; KPL, Gaithersburg, MD) and rabbit IgG
conjugated to HRP (Cell Signaling). Blots were developed using
SuperSignal West Femto Substrate (Thermo). For each time point,
Bmpr2-floxed and Bmpr2-cKO samples were run on the same gels to avoid
across-gel comparison and dashed lines are included to indicate where
lanes are cropped to aid clarity of presentation. Signaling analyses were
quantified by determining the ratio of the phosphorylated (active) SMAD
isoform to the total pool. The validity of this approach is confirmed by the
fact that total SMAD expression levels are unchanged relative to b-actin in
Bmpr2-cKO mice (supplementary material Fig. S1C,D) or with ACVR2B-
Fc treatment (supplementary material Fig. S1E). Band densities were
quantified using ImageJ and normalized to Bmpr2-floxed control. Data are
expressed as group mean6s.e.m. based on each individual ratio. Stripping
of membranes was accomplished using Restore Western Blot Stripping
Buffer (Thermo).
Physiological analysis of bones
Standard histomorphometric analyses were performed on the proximal
tibiae of 10-week-old female mice. To examine mineral apposition rate,
mice were injected intra-peritoneally with 20 mg calcein (Sigma-Aldrich)
per gram body weight at 7 days and 2 days prior to killing. Tibiae were
collected immediately following killing, fixed in 70% ethanol, embedded
in methylmethacrylate without decalcification and sectioned. Parameters
were examined by a blinded scorer. The reader is directed to an excellent
guide to bone histomorphometry (Dempster et al., 2013).
For micro-computed tomography (mCT) analyses, bones were
collected immediately after killing and fixed in 10% neutral buffered
formalin (Millipore, Billerica, MA). Bones were exchanged into 70%
ethanol, stored at 4 C̊, and analyzed at the HSDM mCT Core Facility on a
SCANCO mCT 35 scanner. Bone volume and mineral density were
determined using the following settings: FOV/diameter: 7168 mm; voxel
size: 7.0 mm; slice increment: 7.0 mm; projections: 500; sample time:
600 ms; m-scaling: 4096; energy: 55,000 V; intensity: 145 mA. The
reader is directed to an excellent guide to mCT in rodents (Bouxsein et al.,
2010).
Gene expression analyses
RNA was collected from isolated osteoblasts and marrow-free humerii
from 4-week-old female or 15-week-old male mice using the RNEasy Plus
Universal Kit (QIAGEN, Valencia, CA) after homogenization using a
Bullet Blender (Next Advance). Reverse transcription was performed
using an EcoDry Premix Kit (Clontech, Mountain View, CA). Quantitative
PCR was performed using FastStart Universal SYBR Green Master Mix
(Rox) (Roche, Nutley, NJ) on a StepOnePlus Real-Time PCR System
(Applied Biosystems, Life Technologies) and primers as outlined in
supplementary material Table S2. All primers were designed to cross exon
boundaries and total RNA was treated with DNase. Data were analyzed by
the comparative Ct method relative to cyclophilin B (Ppib Taqman probe,
Mm00478295_m1, Life Technologies) using the equation 22DDCt.
ACVR2B receptor decoy administration
Recombinant human ACVR2B extracellular domain fused to human
IgG1 Fc (ACVR2B-Fc) was obtained as a gift from Regeneron
Pharmaceuticals (Tarrytown, New York, NY). Using the dosing
scheme described by Koncarevic et al. (Koncarevic et al., 2010), male
Bmpr2-floxed and Bmpr2-cKO littermates were treated with 10 mg
ACVR2B-Fc in sterile PBS per gram body weight by intraperitoneal
injection for time period indicated. Body weight was taken on day 0 and
prior to each treatment. Upon killing, bones were processed for mCT as
described above and the pectoralis major muscle was excised, dried at
37 C̊ for two days, then weighed.
Statistical analyses
All quantitative data are expressed as mean6s.e.m. except where
indicated. Statistical significance was determined by unpaired Student’s
t-test for individual pairwise comparisons and one-way ANOVA with
post hoc Newman–Keuls correction for multiple pairwise comparisons
using GraphPad Prism (except where indicated). P,0.05 was considered
significant.
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